{
    "2019-09-12": [
        [
            {
                "time": "",
                "original_text": "医疗器械产业快速发展，政策加码相关标的股仍具配置价值",
                "features": {
                    "keywords": [
                        "医疗器械",
                        "政策加码",
                        "配置价值"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "议市厅丨12000销售代表3000研发人员，上市19年利润激增61倍，恒瑞医药是如何成为A股“医药一哥”的？",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "利润增长",
                        "医药一哥"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "恒瑞医药(600276.SH)：国家药监局已受理卡瑞利珠单抗单药二线治疗晚期食管鳞癌、卡瑞利珠单抗联合培美曲塞加卡铂一线治疗晚期或转移性非鳞癌非小细胞肺癌的上市申请",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "卡瑞利珠单抗",
                        "上市申请"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药板块业绩处于真空期继续配置高性价比品种",
                "features": {
                    "keywords": [
                        "医药板块",
                        "高性价比",
                        "业绩真空期"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "茅台们大跌：黄牛靠边，资金作祟",
                "features": {
                    "keywords": [
                        "茅台",
                        "大跌",
                        "黄牛",
                        "资金"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "消费"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "郑眼看盘：短线稍弱 可继续做多",
                "features": {
                    "keywords": [
                        "短线",
                        "做多"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "美迪西冲刺科创板，下一个药明康德 还是小而美的CRO？",
                "features": {
                    "keywords": [
                        "美迪西",
                        "科创板",
                        "药明康德",
                        "CRO"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "外资入市“解锁” 哪些A股有戏",
                "features": {
                    "keywords": [
                        "外资入市",
                        "A股"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}